EDITORIAL EVALUATION AND POLICIES
All submissions are initially evaluated in depth by the scientific editors. Papers that do not conform to the general criteria for publication will be returned to the authors without detailed review. Otherwise, manuscripts will be sent to reviewers who have agreed in advance to assess the paper rapidly. If revisions are a condition of publication, we generally allow three months for revisions and consider only one revised version of the paper. Evaluations of conceptual advance and significance are made based on the literature available on the day of the final decision, not the day of submission. Any major changes after acceptance are subject to review and may delay publication.
Submission of a manuscript implies that the data have not been published previously and will not be submitted for publication elsewhere while the manuscript is under review. Related manuscripts that have been submitted elsewhere during the period of revision must accompany revised manuscripts. Failure to provide copies of related manuscripts under consideration elsewhere may delay the review process and may be grounds for rejection. Under no circumstances will any paper be considered that contains any data that have been submitted for publication elsewhere.
The corresponding author is responsible for ensuring that all appropriate contributors are listed as authors and that all authors have agreed to the manuscript’s content and its submission to MTM. In a case where we become aware of an authorship dispute, authorship must be approved in writing by all of the parties.
Conflict of Interest
The MTM requires all authors to disclose any financial conflict of interest that might be construed to influence the results or interpretation of their manuscript. Authors must declare any such conflict in the cover letter accompanying the manuscript and in the Acknowledgments section of the manuscript itself. The corresponding author will be asked to sign a form on behalf of all the authors regarding potential conflicts of interest at the time of acceptance. As a guideline, any affiliation associated with a payment or financial benefit exceeding $10,000 p.a. or 5% ownership of a company or research funding by a company with related interests would constitute a conflict that must be declared. This policy applies to all submitted research manuscripts and review material. Examples of statement language include: AUTHOR is an employee and shareholder of COMPANY; AUTHOR is a founder of COMPANY and a member of its scientific advisory board; This work was supported in part by a grant from COMPANY.
Studies Involving Humans and Animals
Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in your paper. Where there is an unavoidable risk of breach of privacy e.g., in a clinical photograph or in case details - the patient's written consent, or that of the next of kin, to publication must be obtained. We will ask you to send a signed consent form before publication. Consent must be obtained for all Case Reports and Clinical Pictures. All experiments on live vertebrates or higher invertebrates must be performed in accordance with relevant institutional and national guidelines and regulations. In the manuscript, a statement identifying the committee approving the experiments and confirming that all experiments conform to the relevant regulatory standards must be included in the Experimental Procedures section. The editors reserve the right to seek comments from reviewers or additional information from authors on any cases in which concerns arise.
Guidelines for Traditional Medicine Resource Names
All scientific names (Latin binomials) must be italicized or underlined throughout the text and in the tables and figures. For plant and animal species, full or complete scientific names, genus-species and the correct authority citation, must be used, when that name appears for the first time in text. The authority citation may be dropped in subsequent mention of that name throughout the text. The family name must follow the scientific name in parentheses when the name appears for the first time in the text. Full scientific names and the family name of the subject plants/animals must be used in the Abstract. Synonyms must be indicated in parentheses and preceded by the word "syn." followed by a colon. Authors are advised to consult the International Plant Name Index (IPNI) (http://www.ipni.org and W3Tropicos (http://www.mobot.org) web-based databases to determine the correct spelling of full plant scientific names. Generic names may be abbreviated, provided such practice does not lead to confusion; generic names, however, must not be abbreviated when the name appears for the first time in the text. Specific epithets must never be abbreviated. The voucher herbarium specimen number of the plant(s) studied in case of less well known plants, cited using the collector and collection number, and indicating the name of the herbarium institution where it has been deposited.
Upon acceptance of an article, authors will be asked to transfer copyright. This transfer will ensure the widest possible dissemination of information. A form facilitating transfer of copyright will be provided upon acceptance of the manuscript. After transfer of copyright, authors retain rights as discussed below.
As an author you (or your employer or institution) may do the following:
Make copies (print or electronic) of the article for your own personal use, including for your own classroom teaching use;
Make copies and distribute such copies (including through e-mail) of the article to known research colleagues, for the personal use by such colleagues (but not for commercial purposes as described below);
Post a revised personal version of the final text (including illustrations and tables) of the article (to reflect changes made in the peer review and editing process) on your personal or your institutional website or server, with a link to the article as published, provided that such postings are not for commercial purposes as described below;
Present the article at a meeting or conference and to distribute copies of the article to the delegates attending such meeting;
For your employer, if the article is a ‘work for hire,’ made within the scope of your employment, your employer may use all or part of the information in the article for other intra-company use (e.g., training);
Retain patent and trademark rights and rights to any process or procedure described in the article;
include the article in full or in part in a thesis or dissertation (provided that this is not to be published commercially);
Use the article or any part thereof in a printed compilation of your works, such as collected writings or lecture notes (subsequent to publication of the article in the journal); and
Prepare other derivative works, to extend the article into book-length form, or to otherwise re-use portions or excerpts in other works, with full acknowledgement of its original publication in the journal.
All copies, print or electronic, or other use of the paper or article must include the appropriate bibliographic citation for the article’s publication in the journal. However you should not indicate in the citation that the version that you are reproducing or posting is the final published version as published in the journal. As an example, it may be appropriate to indicate “This paper has been submitted to [Journal] for consideration.”
Commercial purposes include: the posting by companies or their employees for use by customers (e.g., pharmaceutical companies and physician-prescribers); commercial exploitation such as associating advertising with such posting (including the linking to advertising by search engines); the charging of fees for document delivery or access; or the systematic distribution to others via e-mail lists or list servers (to parties other than known colleagues), whether for a fee or for free.
The MTM seeks to publish Review articles that collect, collate, and compare observations on a topic of broad interest to the readership of the Journal. The ideal Review should be accurate scientifically; describe the most relevant and recent contributions; be fair in its appraisal of the significance of the studies cited; and be generous in the choice of citations, giving equal notice to contributions from both collaborators and competitors, and consider the work published throughout the international community.
To submit review article, you will need:
(a). A cover letter describing the focus of your proposed paper
(b). An abstract of no more than 300 words that should arouse the readers' interest, be written for a general readership, and be free from special jargon
(c). A title and a complete list of authors
(d). Schematic illustration(s) that depict the most important points that are described in the body of the text. These illustrations should be attached to your review article.
Minireviews discuss a sharply focused scientific topic of interest, usually highlighting emerging themes from papers in the recent literature. They cover a focused area on the advancing edge of eastern medicine and provide a balanced view of current research that can be understood by researchers outside of that specialty. Minireviews must fit within 4 pages of the journal and therefore should be no more than 18,000 characters including references and figure legends, with up to 20 references and one or two figures.
Research Articles present conceptual advances of unusual significance regarding eastern medicine at the molecular level. Research papers should be as concise as possible and written in a style that is accessible to the broad MTM readership.
These papers describe, in 600 words, a single interesting case, which should not be a rarity but one that a general physician might encounter, in which there was some difficulty in reaching a diagnosis, and that provides a teaching point. Preferably the case should have a good illustration. Consent for publication in print and electronically must be obtained from the patient.
Cutting Edge is the rapid publication section of MTM, presenting short reports describing significant advances in an area of eastern medicine at the molecular level. Cutting Edge should not exceed four pages in print (approx. 2,000-3,000 words including abstract, captions and references). A maximum of 2 illustrations (figures and tables) is allowed. An abstract of not more than 100 words should be provided and 3-6 keywords should be listed immediately below the abstract.
The MTM encourages authors to submit manuscripts by e-mail to http://www.moltm.org .If you are unable to submit your manuscript by e-mail, a copy of the manuscript may be sent to Editor-in-Chief, MTM, College of Oriental Medicine, Kyung Hee University, 1 Hoegi-Dong, Dongdaemun-Gu, Seoul 130-701, Republic of Korea. Please include a CD with electronic files of cover letter, text, and figures, as separate files.
Each submission should be accompanied by a cover letter, which should contain a brief explanation of what was previously known, the conceptual advance provided by the findings, and the significance of the findings to a broad readership. A cover letter may contain suggestions up to five requests for appropriate reviewers. The cover letter is confidential to the editor and will not be seen by reviewers.
General Article Organization and Text Specifications
The MTM Research articles generally contain the following sections in this order: Title, Authors, Affiliations, Contact Information, Additional title page Footnotes, Abstract, Introduction, Results, Discussion, Experimental Procedures, Acknowledgements, References, Figure and Table Legends, Figures and Tables, Supplemental Data. The text (Title through Legends) should be provided as one document, which may also contain the Tables. Figures should be provided separately. Supplemental Data should be provided separately.
Gene symbols should be italicized; protein products of the loci are not italicized. Nonstandard abbreviations should be defined when first used in the text. Use of abbreviations should be kept at a minimum. Manuscript file type that we can accept for submission is in Microsoft Word. Please note that the text should be double spaced and pages should be numbered.
Manuscripts that do not conform to the format guidelines may be returned to the authors for reformatting.
Preparation of Specific Sections
Titles can occupy no more than five lines of type. The title should convey the conceptual significance of the paper to a broad readership.
Author names should be spelled out rather than set in initials. Authors should be footnoted to corresponding affiliations. Affiliations should contain the following core information: department(s)/subunit(s); institution; city, state/region, postal code; country.
The contact line should include the e-mail address and phone/fax numbers of the corresponding author. The published corresponding author is responsible for ensuring adherence to all editorial and submission policies and for any communications that may result post-publication. One corresponding author is preferred, but two are allowed.
Footnotes are only allowed on page 1 of the text (and in tables). They may include a present address or statement of equal contribution to the manuscript.
The text should include a running title of no more than 50 characters including spaces.
The Abstract consists of a single paragraph of fewer than 250 words. It should clearly convey the conceptual advance and significance of the work to a broad readership. In particular, the abstract should contain a brief background of the question, a description of the results without extensive experimental detail, and a summary of the significance of the findings. References should not be cited in the Summary.
The Introduction should be succinct, with no subheadings, and should present the background information necessary to provide a context for the results.
This section should be divided with subheadings. Footnotes should not be used and will be transferred to the text.
The Discussion should explain the significance of the results and place them into a broader context. It should not be redundant with the Results section. This section may contain subheadings and can in some cases be combined with the Results section.
The Experimental Procedures section needs to include sufficient detail so that readers can understand how the experiments were done, and so that all procedures can be repeated, in conjunction with cited references. This section should also include a description of any statistical methods employed in the study. A more detailed version of the procedures and details such as oligo sequences, strains, and specifics of how constructs were made can be included in Supplemental Data, but it is not appropriate to move the majority of the Experimental Procedures to Supplemental Data in order to shorten the text.
This section may acknowledge contributions from non-authors, list funding sources, and should include a statement of any conflict of interests. Please check this section carefully, as we are unlikely to make amendments or publish corrections post-publication. This section may be used to list the contributions of individual authors.
References should include only articles that are published or in press. Unpublished data, submitted manuscripts, abstracts, and personal communications may be referred to in the text but should not appear in the list of references. Personal communication should be documented by a letter of permission. Submitted articles should be cited as unpublished data, data not shown, or personal communication. References should be listed alphabetically (see sample references). Articles written by the same first author with different second authors should be listed according to the first author’s surname and then according to the second author’s surname. Articles written by the same first author with more than one co-author should be listed alphabetically according to the first author’s surname and then according to the year of publication. Two or more references to the same first author with the same publication year should have a,b,c etc. suffixed to the year indicating the alphabetical order of the second or third author, etc. References to journals should contain the names and initials of the author(s), the full title, the abbreviation of the name of the periodical according to the ISO Abbreviations, followed by the year, volume and page numbers. References to books should include the title and name and city of the publisher. References in the text should be cited by the author’s name(s) and the year of publication. Examples: Kim (1997) or Um and Kim (2003) and (Kim, 1997; Kim and Um, 2006; Um and Moon, 2003). For three or more authors the name of the first author followed by et al. should be used. Examples: Um et al., (2005) and (Um et al., 2002, 2003; Um et al., 2005, 2006a,b,c).
Please use the following style for references:
Article in a periodical:
Jeong HJ, Na HJ, Hong SH, Kim HM. Inhibition of the stem cell factor-induced migration of mast cells by dexamethasone. Endocrinology 2003;144:4080-4086.
Um JY, Kim HM. Frequencies of interleukin 1 gene polymorphisms in Koreans. Clin Chem 2003;49:2101-2102.
Article in a book:
King SM. Dynein motors: Structure, mechanochemistry and regulation. In Molecular Motors, Schliwa M ed. (Weinheim, Germany: Wiley-VCH Verlag GmbH), pp. 45?78, 2003.
An entire book:
Cowan WM, Jessell TM, Zipursky SL. Molecular and Cellular Approaches to Neural Development (New York: Oxford University Press), 1997.
Legends should be included in the submitted manuscript as a separate section. Each figure legend should have a brief title that describes the entire figure without citing specific panels, followed by a description of each panel. For any figures presenting pooled data, the measures should be defined in the figure legends (for example, data are represented as mean ± S.E.M.).
When creating a table, please use the Microsoft Word table function and do not place an Excel table in a Word document. Word tables should not be tab or space delineated and should not use color. Tables should include a title, and footnotes and/or legend should be concise. Include tables in the submitted manuscript as a separate section. Tables should not have vertical lines, and horizontal lines must be kept to a minimum. Tables not created using the Microsoft Word table function will need to be revised by the author.
(a) Tables should not duplicate material in text or illustrations
(b) Short or abbreviated column headings should be used and if necessary, explained in footnotes, and indicated as a,b,c, etc.
(c) Statistical measures of variation, S.D., S.E., M., etc. should be identified.
Supplemental data are restricted to items that are directly pertinent to the conclusions of the paper. Editors reserve the right to limit the scope and length of Supplemental Data. Supplemental Data should be provided with the original submission. Please follow the digital figure guidelines below for preparing figures. In general, supplemental files (movies, databases, tables, etc.) must each be less than 10 MB. All figures and tables should have titles and legends. In general, every attempt should be made to submit the Supplemental Data in a composite Word file.
Abbreviations are a hindrance for the reader. Use as few abbreviations as possible and write out names of compounds, receptors, etc., in full throughout the text of the manuscript, with the exceptions given below.
(a) Unnecessary abbreviations. Unnecessary abbreviations such as AP, TEP, TFT, CER, nAc and LTFSE (for afterpotential, transepithelial potential, Tail-flick test, cold-exposed rats, nucleus accumbens and sympatho-excitatory lateral tegmental field) are not acceptable.
(b) Receptor abbreviations. Receptor abbreviations such as bAR, mAChR, BZR for b-adrenoceptor, muscarinic receptor, benzodiazepine receptor, respectively, should not be used. For receptors avoid the abbreviation "R". With receptor subtypes mention the full receptor name throughout the manuscript e.g., adenosine A1 receptor, dopamine D2 receptor, melanocortin MC3 receptor, endothelin ETA receptor.
(c) Generic names. Generic names should not be abbreviated. For example, AMP, HAL, HIST, RAMH, TAM, SST, for amphetamine, haloperidol, histamine, (R)-a-methylhistamine, tamoxifen, somatostatin, are not accepted. Abbreviations such as (e.g., NA, DA, ACh, ET for noradrenaline, dopamine, acetylcholine, endothelin, should not be used.)
(d) Abbreviations which have come to replace the full term. Abbreviations which have come to replace the full term (e.g., GABA, DOPA, EDRF, 5-HT, for g-aminobutyric acid, 3,4-dihydroxyphenylalanine, endothelium-derived relaxing factor, 5-hydroxytryptamine) may be used, provided the term is spelled out in the abstract and in the body of the manuscript the first time the abbreviation is used.
(e) Unwieldy chemical names. Unwieldy chemical names may be abbreviated. For example, 8-OH-DPAT, DOI, DTG, BAPTA, for 8-hydroxy-2-(di-n-ropylamino)tetralin, 1-(2,5-dimethoxy-4-iodophenyl)-aminopropane, 1,3-di(2-tolyl)-guanidine, 1,2-bis(oaminophenoxy) ethane-N,N,N’,N’-tetraacetic acid, are acceptable; however, the full chemical name should be given once in the abstract and in the body of the manuscript, followed in both cases by the abbreviation.
(f) Code names. Code names may be used, but the full chemical name should be given in the abstract and in the text.
Authors not conforming to these demands will have their manuscripts returned for correction, with delayed publication as the result.
Some abbreviations may be used without definition:
ADP,CDP 5’-pyrophosphates of adenosine
GDP,IDP cytidine, guanosine, inosine
AMP etc. adenosine 5’-monophosphate etc.
ADP etc. adenosine 5’-diphosphate etc.
ATP etc. adenosine 5’-triphosphate etc.
CoA and acetyl-CoA coenzyme A and its acyl derivatives
DNA deoxyribonucleic acid
EGTA ethylene glycol-bis(b-aminoethyl ether)N,N,N’,N’-tetraacetic acid
FAD flavin-adenine dinucleotide
FMN flavin mononucleotide
GSH, GSSG glutathione, reduced and oxidized
HEPES 4-(2-hydroxyethyl)-1-piperazine-ethanesulphonic acid
NAD nicotinamide-adenine dinucleotide
NADP nicotinamide-adenine dinucleotide phosphate
NMN nicotinamide mononucleotide
Pi, PPi orthophosphate, pyrophosphate
RNA ribonucleic acid
Abbreviations of units of measurements and other terms are as follows:
Units of mass
mole (gram-molecule) mol
Units of time
Units of volume
Units of length
Units of concentration
molar (mol/l) M
Units of heat, energy, electricity
degree Celsius (centigrade) °C
Units of radiation
counts per minute cpm
disintegrations per minute dpm
dissociation constant Kd
median doses LD50, ED50
routes of drug administration i.v., i.p., s.c., i.m., i.c., i.t., i.c.v., i.v.t., p.o.
square centimetre cm2
standard deviation S.D.
standard error of the mean S.E.M.
Svedberg unit of sedimentation coefficient S
Hill coefficient nH
The isotope mass number should appear before the atomic symbol, e.g., [3H]noradrenaline, [14C]choline. Ions should be written: Fe3+, Ca2+,Mg2+. The term absorbance (A) is preferred to extinction or optical density.
Figure organization, Formats, and style
Figures must conform to the following guidelines or authors will be asked to revise them. For figures that have multiple panels, the labels should be set in uppercase Helvetica or Arial letters and should not contain periods or parentheses. Please be sure to embed all fonts. Each figure must be assembled into one file that prints onto one 8 1/2 × 11 page. Please do not include separate panels on multiple pages. Micrographs should be provided with a scale bar, if appropriate, instead of magnification.
Acceptable Image Formats for E-mail Submission:
Portable Document File (.pdf)
JPEG (.jpg) use maximum quality
Please note that we cannot accept PowerPoint, Adobe Photoshop, or Adobe Illustrator files for e-mail submission through Editorial Manager.
These files must be converted to one of the above file types. Converting PowerPoint files frequently results in unexpected changes to the figures (e.g., missing or shifted text; shifted image elements). We recommend that you not create figures in PowerPoint. If you do try to convert from PowerPoint to one of these file types, be very careful to compare the final version to your original.
We also cannot accept image files in Canvas, Freehand, or Microsoft Word.
TIFF Files (.tif)
TIFF is our preferred format.
As with all vector files (Adobe Illustrator, etc.), when saving as .eps, please be sure to embed all fonts or convert to outlines or paths.
Postscript Files (.ps)
There are many different drawing programs, not all of them supported by the software we use. From almost all of these programs, you should be able to produce a postscript file. When printing, select to print to a (postscript) file, rather than printing by default to a printer. The image must be in portrait orientation. Please be sure to embed all fonts when you save as postscript.
For black and white photographs or micrographs and for any type of graph or drawing in grayscale, the resolution of your file should be a minimum of 500 dpi. For figures that contain color, the resolution should be a minimum of 300 dpi. Please note that figures should meet these resolution numbers at their approximate print sizes.
We encourage authors to use colors that can be distinguished by color-blind readers. Please submit your figures in RGB or grayscale -- do not convert your files to CMYK. This will optimize their appearance online. However, please be aware that we will convert to CMYK for the print version. If possible, embed the ICC profile.
Please make sure that all graph lines, error bars, and outlines are at least ½ point in weight. Lines that are less than ½ point may disappear or be broken during printing.
If you have any questions about digital files, please contact us, at http://www.moltm.org.
SUBMISSION OF REVISED MANUSCRIPTS
Revised manuscripts must contain a detailed point by point response to the comments of the reviewers and/or editors. The cover letter should briefly summarize how the revised manuscript addresses these comments. In general, revised manuscripts will be reconsidered only if resubmitted within three months of the date of the original decision.
CHECKLIST FOR FINAL SUBMISSION
In order for a paper to be accepted and scheduled for publication, the author will be asked to send the following items.? Please refer to the letter from your editor for further details and to the additional guidelines below for final figures.
1. Please make sure your final manuscript:
Includes database accession numbers for new gene sequences, protein sequences, structures, or microarray data
Includes explanation of statistical methods in the Experimental Procedures
For any figures presenting pooled data, defines the measures in the figure legends
Includes experimental procedures of sufficient detail
2. Please send to us:
In hard copy:
One printed copy of the text
Two high-quality glossy hard copies of each figure (including supplemental)
A signed copy of the conflict of interest statement
On a single CD:
A modifiable electronic version of the final text
High-resolution digital files of the figures in an accepted format
Supplemental dataset as a single Word document with embedded figures and tables
Additional supplemental data such as movies and spreadsheets
Figure Formats Acceptable for Final Submission:
Portable Document File (.pdf)
JPEG (.jpg) use maximum quality
Adobe Illustrator (all versions) (.ai)
Please note that we cannot accept PowerPoint files. (See note under Figure Organization, Formats, and Style above).
Please name files by first author and number of figure, e.g., Smith1.tif, Smith2.tif, etc.
Production and Proofs
After final acceptance, the manuscript will be passed to the production team to be copyedited and prepared for printing. Authors will be charged $200 for the first color figure and $200 for each additional color figure. Figures may be resized during the production process.
PDF proofs will arrive via email about 2 weeks prior to publication and need to be returned with vital corrections no more than 24 hours after receipt. If you will be unreachable at all during this period or anticipate any problems meeting this timeline, please contact Jae-Young Um, Managing Editor (email@example.com ).